MarginsXMarginsX
Home › Markets › Health Care › RDY

Dr. Reddy's Laboratories Ltd (RDY)

RDY trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$14.70
-0.27% on the day
Market cap
$12.3B
Large cap
Revenue · 2025
$3.6B
-6.5% on 2024
Net income · 2025
$454.7M
12.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1135951/000157587226000381/0001575872-26-000381-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2026-03-31. Converted from INR at 94.2431 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerRDY on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIndia
IPO yearNot reported by the screener
SEC CIK0001135951
SEC industry codePharmaceutical Preparations
Incorporated inIndia

Financials · 2025

LineValue
Revenue$3.6B
Net income$454.7M
Operating income$536.4M
Net margin12.8%
Operating margin15.0%
Revenue growth-6.5%
Cash$163.1M
Total assets$6.1B
P/E (computed)27.0×
P/S (computed)3.4×

Reported in INR; shown in US dollars.

Warning signs

Cash runway
Cash-flow positive
$163.1M cash at March 31, 2026
Share count, 1 year
0.0%
2025-03-31 to 2026-03-31 · +0.2% over 3 years
Going-concern doubt
No
20-F filed May 29, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-05-29
Cash and burn$163.1M cash; operating cash flow $150.6M a quarter.Report 2026-03-31
Shares outstanding834,656,970 (2026-03-31); 834,455,365 a year earlier; 166,527,876 three years earlier. 3y figure adjusted for splits (5-for-1 overall); the newest SEC cover-page count is from 2026-03-31; shares issued since then are not in these figures.Cover page 2026-03-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young Associates LLP, Hyderabad, IndiaPCAOB Form AP 2026-06-22
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2026
2026-03-31
$3.6B$454.7M$602.2M$163.1M$193.2M$3.6B20-F 2026-05-29
FY 2025
2025-03-31
$3.8B$663.0M$545.0M$172.0M$537.0M$3.8B20-F 2025-06-06
FY 2024
2024-03-31
$3.4B$668.0M$545.0M$85.0M$225.0M$3.4B20-F 2024-06-12
FY 2023
2023-03-31
$3.0B$548.0M$716.0M$70.0M$106.0M$3.0B20-F 2023-06-13
FY 2022
2022-03-31
$2.8B$311.0M$370.0M$196.0M$433.0M$2.8B20-F 2022-06-27
FY 2021
2021-03-31
$2.6B$236.0M$488.0M$203.0M$402.0M$2.6B20-F 2021-06-30
FY 2020
2020-03-31
$2.3B$259.0M$396.0M$27.0M$235.0M$2.3B20-F 2020-06-15
FY 2019
2019-03-31
$2.2B$272.0M$415.0M$32.0M$493.0M$2.2B20-F 2019-06-03

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest annual report
FORM 20-F
20-F2026-05-29
Latest quarterly / interim
FORM 6K
6-K2026-11-16

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.1%
1 month+15.4%
3 months+18.7%
Year to date+5.0%
1 year+6.3%
From 52-week high-4.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ELANElanco Animal Health Incorporated$26.41-1.38%$13.2B
BMRNBioMarin Pharmaceutical Inc.$57.99+1.33%$11.2B
BBIOBridgeBio Pharma Inc.$77.36-1.20%$15.1B
MDGLMadrigal Pharmaceuticals Inc.$423.96-0.80%$9.8B
JAZZJazz Pharmaceuticals plc Common Stock (Ireland)$239.77-0.74%$15.4B
TGTXTG Therapeutics Inc.$62.76-2.71%$9.5B
SMMTSummit Therapeutics Inc. Common Stock$11.82-16.47%$9.5B
SYRESpyre Therapeutics Inc.$99.37-4.45%$9.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier